The efficacy of anti‐CTLA‐4 TGF‐βRIIecd in reducing Treg activity in TME and hampering tumour progression is superior to that for the CTLA‐4 inhibitor ipilimumab. The gene discussed is CTLA4; the disease is neoplasm.